ArticleJournal of primary care & community health
Candesartan, Metoprolol and Rosuvastatin Associated to Lower 30-Days Mortality in Adult COVID-19 Patients - A Register Study in Finland before COVID-19 Vaccines.
Article in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elderly people with chronic diseases are at risk for having severe COVID-19 disease. We were interested whether the drugs prescribed for the chronic diseases are associated with lower mortality in COVID-19 patients.We used Finnish national registry data for analysis of potential associations of 73 prescription drugs to mortality among 6082 adult COVID-19 patients between 1.1.2020 and 30.6.2020, before COVID-19 vaccinations were available. Adjusted odds ratios (aORs) with 95 percent confidence intervals (95% CIs) for different medications are presented.The use of three cardiovascular drugs was associated with lower 30 days all-cause mortality rate: candesartan (aOR 0.34, 95% CI 0.16-0.72, p=0.005), metoprolol (aOR 0.37, 95% CI 0.16-0.88, p=0.024) and rosuvastatin (aOR 0.44, 95% CI 0.21-0.94, p=0.034).In conclusion, COVID-19 patients who used cardiovascular drugs candesartan, metoprolol or rosuvastatin have lower 30 days all-cause mortality than other COVID-19 patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.